Accent Therapeutics, Inc. ’s Post

Springer Healthcare's official partnership with #ASCO is one of my favourite things about working here. Official ASCO content + Springer-led expert commentary is one of the things our learners value about our accredited programs. AND it means both Springer Nature and ASCO can co-market to reach both our audiences #CME #IME #NSCLC #oncology #meded #medicaleducation #independentmedicaleducation #SpringerHealthcareIME

Going to Chicago for ASCO 2024? If so, let's connect! We are eager to share what we have been up to since last ASCO in enabling healthcare providers to piece together a complete picture of their cancer patient's journey with our CELLSEARCH (CTC enumeration) and MenariniSearch (cfDNA/cfRNA genomic profile) tests. Request a Meeting Today! Cancer Counts Our tests using the CELLSEARCH® platform offer a minimally invasive approach to follow your cancer patient’s therapeutic journey by analyzing rare circulating tumor cells. Several of these tests include a phenotyping reagent for HER2, ER, and PD-L1, allowing you to identify patients who may benefit from biomarker targeted therapies. All of our tests provide a standardized and reliable count of circulating tumor cells that help you to make more informed clinical decisions—all with a simple blood draw. Search the Tissue. Search the Liquid. Search More Mutations MenariniSearch comprehensive genomic profiles enable you to identify a broader range of genetic alterations, empowering you to discover novel biomarkers and therapeutic targets that could enhance patient care. The tests use next-generation sequencing powered by artificial intelligence and are reviewed by pathologists. *The MSB lab in Huntingdon Valley, PA is CLIA Certified and ISO 15189-accredited, with licenses from New York, California, Maryland, Pennsylvania, Washington DC and Rhode Island. *HER2+ CTCs are cells of epithelial origin that are EpCAM+, Cytokeratin+, CD45-, and HER2+. The HER2 assay data is reported as number of HER2+ CTC/7.5 mL of whole blood, a positive test is HER2+ CTCs ≥ 1. The CELLSEARCH® Circulating Tumor Cell Test is FDA-cleared for the enumeration of CTCs in patients with metastatic breast, colorectal, and prostate cancers.The CELLSEARCH® CTC Enumeration with HER2 Biomarker assay is a validated Laboratory Developed Test within a CLIA certified laboratory, and is not cleared or approved by the FDA. *MenariniSearch tests performance, characteristics, safety, and effectiveness have been validated and are offered through a CLIA-certified Clinical Laboratory; they are lab-developed tests and have not been cleared or approved by the FDA. https://lnkd.in/dge-Ukpk #ASCO24 #ctc #cfdna #cfrna #oncology

📢 150 Bispecific relevant abstracts presented at ASCO 2024! 📢 CD3 targeting bispecifics dominate the landscape, with common combinations with BCMA (for the treatment of multiple myeloma) and CD20 (for the treatment of lymphoma). Analysis and summaries of the abstracts can be found in the snippet of our recently published report below:

"🔥 Exciting news! 🚀 Join us for the upcoming ISVIR Masterclass Onco Intervention Series as we dive into insights that will revolutionize the field! 🏥💡 Already conquered GI and general interventions! Fill the form to get all updates on mail! https://lnkd.in/grBZgAv2 📧✉️ #ISVIR

Schedule a meeting with the experts from Discovery Life Sciences at #ASCO24

ASCO 2024 is set to discuss several critical areas that are directly relevant to the daily challenges and strategic goals of Clinical Operations executives. Meet with Medelis at #ASCO24 to learn more - https://ow.ly/YOWp50RzWmz

Now that the first QHINs are operational under TEFCA, how will this improve interoperability? Moxe’s Director of Channel Partnership, Greg Meltzer, breaks down why this progress is important, but just the first step in the right direction. Read more on our blog: https://hubs.li/Q02hMNQj0 #TEFCA #QHIN #ONC #ClinicalDataExchange

3CTN will be hosting the next impACCT Virtual Rounds session on October 22, 2024, at 12 pm ET. We will be discussing the following two trials: Trial #1: (CCTG) SC.29: A Randomized Phase III Trial Comparing Stereotactic Body Radiotherapy to Conventional Palliative Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Participants With Painful Non-Spine Bone Metastases Speaker: Dr. Arjun Sahgal Trial #2: (CCTG) AL.6 / MM1YA-CTG01: A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial Speaker: Dr. Sarit Assouline To register for the session, click here: https://lnkd.in/dJNTVejv

Results from the phase III KRYSTAL-12 trial were presented by Dr. Tony Mok during the 2024 ASCO Annual Meeting. Read a recap in ILCN: https://bit.ly/3xrtdhh #LCSM

How can we help accelerate your oncology clinical trial milestones? Meet with my LabConnect colleagues during #ASCO to find out!